Is the price fair?
What RVTY's price assumes
Revvity trades at 60.5× earnings against 35.3× for the median Diagnostics & Research name, more expensive than its own group.
60.5
Trailing P/E · Diagnostics & Research median 35.3 · 1.71× the median: the market pays up for this one
- Price / sales
- 3.43
Price / sales · as of 2026-Q1
- Free cash flow yield
- 5.0%
Free cash flow yield · Diagnostics & Research median 4.2%
- Growth the price implies
- +5.6%
Growth the price implies · The price pays for +5.6% free cash flow growth a year for a decade; the business has delivered +54% a year over the last three.
Details›
- Price / book2026-Q1
- 1.38
- EV / EBIT2026-Q1
- 32.5
- EV / sales2026-Q1
- 4.04
- Healthcare median P/E362 names
- 31.5
- Diagnostics & Research median P/E29 names
- 35.3
- Free cash flow, trailing twelve months
- $558M
- Market capitalisation
- $11.2B
- 3-year revenue growth
- +0.87%
- 3-year free cash flow growth
- +54%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $49.70 |
| Its own P/E history, median | $71.80 |
| Its own P/E history, upper quartile | $94.70 |
| 52-week range | $82.26 – $126.36 |
| Today | $126.37 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Diagnostics & Research
Ranks #26 of 29 by Smart Score